References
- Andrews F. M. Observations on lactic dehydrogenase activity in blood of patients treated with D‐penicillamine for rheumatoid arthritis. Current Med Res Opin 1974; 2: 587
- Anonymous. D‐penicillamine in rheumatoid arthritis. Lancet 1973; 1: 1123
- Barzilai D., Dickstein G., Enat R., Bassan H., Lichtig C., Gellei B. Cholestatic jaundice caused by D‐penicillamine. Ann Rheum Dis 1978; 37: 98
- Garber E., Craig R. M., Bahu R. M. Aspirin hepatotoxicity. Ann Int Med 1975; 82: 595
- Gardner D. L. The Pathology of Rheumatoid Arthritis. Edward Arnold, London 1972; 147–148
- Hägerstrand I. Bile canalicular alkaline phosphatase and disease. Acta Pathol Microbiol Scand, Sect A 1976; 84: 271
- Jain S., Scheuer P. J., Samourian S., McGee J. O. D., Sherlock S. A controlled trial of D‐penicillamine therapy in primary biliary cirrhosis. Lancet 1977; 1: 831
- Rau R., Weber S., Böni A. Allergisch‐toxische Leberschadigung durch ppenizillamin. Schweiz Med Wschr 1972; 102: 1226
- Stern R. B., Wilkinson S. P., Howorth P. J. N., Williams R. Controlled trial of synthetic D‐penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 1977; 18: 19
- Webb J., Whaley K., MacSween R. N. M., Nuki G., Dick W. C., Buchanan W. W. Liver disease in rheumatoid arthritis and Sjogren's syndrome. Ann Rheum Dis 1975; 34: 70
- Weinbren K. The liver in Systemic Pathology2nd ed, W. St. Symmers. Churchill Livingstone, Edinburgh, London and, New York 1978; vol. 3: 1248
- Weiss A. S., Markenson J. A., Weiss M. S., Kammerer W. H. Toxicity of D‐penicillamine in rheumatoid arthritis. Am J Med 1978; 64: 114
- Wolfe J. D., Metzger A. L., Goldstein R. C. Aspirin hepatitis. Ann Int Med 1974; 80: 74